Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Summary

The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “No patients were enrolled, study cancelled before start”

Drugs

Indications